Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Shares Sold by Newman Dignan & Sheerar Inc.

Newman Dignan & Sheerar Inc. trimmed its stake in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 4.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,872 shares of the company’s stock after selling 550 shares during the quarter. Newman Dignan & Sheerar Inc. owned 0.27% of Invesco Biotechnology & Genome ETF worth $723,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Massachusetts Wealth Management grew its stake in Invesco Biotechnology & Genome ETF by 1.3% during the 4th quarter. Massachusetts Wealth Management now owns 18,414 shares of the company’s stock worth $1,225,000 after purchasing an additional 230 shares in the last quarter. IHT Wealth Management LLC boosted its position in shares of Invesco Biotechnology & Genome ETF by 14.7% during the 3rd quarter. IHT Wealth Management LLC now owns 12,124 shares of the company’s stock worth $847,000 after acquiring an additional 1,550 shares in the last quarter. HighTower Advisors LLC boosted its position in shares of Invesco Biotechnology & Genome ETF by 64.1% during the 3rd quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock worth $494,000 after acquiring an additional 2,774 shares in the last quarter. Creative Financial Designs Inc. ADV boosted its position in shares of Invesco Biotechnology & Genome ETF by 5.6% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock worth $393,000 after acquiring an additional 299 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Invesco Biotechnology & Genome ETF during the 3rd quarter worth about $295,000.

Invesco Biotechnology & Genome ETF Stock Performance

NYSEARCA:PBE opened at $67.97 on Friday. The stock has a 50-day simple moving average of $68.27 and a 200-day simple moving average of $69.14. The stock has a market cap of $274.60 million, a P/E ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a 1 year low of $59.32 and a 1 year high of $72.84.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.